# MK0354 Clinical Efficacy and Tolerability Study (0354-004)

> **NCT00337415** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 65 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** MK0354

## Key facts

- **NCT ID:** NCT00337415
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2015-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00337415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00337415, "MK0354 Clinical Efficacy and Tolerability Study (0354-004)". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00337415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*